- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03169725
A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
August 27, 2019 updated by: LG Chem
A Prospective, Multi-national, Multi-center, Double-blind, Randomized, Active Controlled, Parallel-group, Seamless Phase II/III Clinical Study to Evaluate the Safety and Immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' Compared With 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in Healthy Infants
The purpose of the study is to evaluate safety and immunogenicity of inactivated poliomyelitis vaccine based on Sabin strain (LBVC) in healthy infants to select optimal dose of LBVC as well as to demonstrate the lot-to-lot consistency and non-inferiority of LBVC.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
1417
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alabang, Philippines
- Research Institute for Tropical Medicine
-
-
-
-
-
Bangkok, Thailand
- Mahidol University Faculty of Medicine Siriraj Hospital
-
Chiang Mai, Thailand
- Chiang Mai University Maharaj Nakhon Chiang Mai Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy infants of either sex who have reached at least 42 days (6 weeks) of age and not more than 56 days (8 weeks) of age at the time of enrollment
- Born at full term of pregnancy (Gestational age ≥37 weeks)
- Body weight ≥ 3.2 kg at the time of screening
- Born to HIV negative mother
- The parents or Legally Acceptable Representative (LAR) able to understand and comply with planned study procedures
- Signed informed consent by subject's parents or Legally Acceptable Representative (LAR)
Exclusion Criteria:
- Previously received any polio vaccines (OPV or IPV)
- History of previous or concurrent vaccinations other than HepB, BCG, DTP, Hib, Rotavirus vaccine and PCV
- History of bleeding disorder contraindicating intramuscular injection.
- Experienced fever ≥ 38 °C/ 100.4 °F within the past 3 days prior to the screening
- Receipt of immunoglobulin or blood-derived product since birth
- History of allergic reactions to any vaccine components, including excipients and preservatives (neomycin, streptomycin and polymyxin B, etc.)
- Known or suspected immune disorder, or received immunosuppressive therapy
- History of poliomyelitis
- History of any neurological disorders or seizures
- Known or suspected febrile, acute or progressive illness
- Household contact and/or intimate exposure in the previous 30 days to an individual with poliomyelitis
- Participation in another interventional trial within 30 days before to the enrollment or simultaneous participation in another clinical study
- Infants whose families are planning to leave the area of the study site before the end of the study period
- Infants who is considered unsuitable for the clinical study by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test group 1
Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
|
Investigational IPV based on Sabin strain (LBVC).
Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
|
Experimental: Test group 2
Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
|
Investigational IPV based on Sabin strain (LBVC).
Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
|
Experimental: Test group 3
High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
|
Investigational IPV based on Sabin strain (LBVC).
Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
|
Active Comparator: Comparator
Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
|
Commercialized IPV based on Salk strain (Imovax Polio).
Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage1: Seroconversion rate(%)
Time Frame: 4 weeks after 3rd vaccination
|
Proportion of subjects achieving seroconversion of each poliovirus serotype using microneutralization assay
|
4 weeks after 3rd vaccination
|
Stage2: Seroconversion rate(%)
Time Frame: 4 weeks after 3rd vaccination
|
Proportion of subjects achieving seroconversion of each poliovirus serotype using microneutralization assay
|
4 weeks after 3rd vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage1: Seroconversion rate (%)
Time Frame: 4 weeks after 2nd vaccination
|
Proportion of subjects achieving seroconversion of each poliovirus serotype using microneutralization assay
|
4 weeks after 2nd vaccination
|
Stage2: Seroprotection rate (%)
Time Frame: 4 weeks after 3rd vaccination
|
Proportion of subjects achieving seroprotection of each poliovirus serotype using microneutralization assay
|
4 weeks after 3rd vaccination
|
Stage1: GMTs (Geometric Mean Titers)
Time Frame: 4 weeks after 2nd and 3rd vaccination
|
Comparison of GMTs and GMT ratios
|
4 weeks after 2nd and 3rd vaccination
|
Stage2: GMTs (Geometric Mean Titers)
Time Frame: 4 weeks after 3rd vaccination
|
Comparison of GMTs and GMT ratios
|
4 weeks after 3rd vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2017
Primary Completion (Actual)
January 18, 2019
Study Completion (Actual)
June 14, 2019
Study Registration Dates
First Submitted
May 11, 2017
First Submitted That Met QC Criteria
May 25, 2017
First Posted (Actual)
May 30, 2017
Study Record Updates
Last Update Posted (Actual)
August 29, 2019
Last Update Submitted That Met QC Criteria
August 27, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Neuromuscular Diseases
- Central Nervous System Infections
- Enterovirus Infections
- Picornaviridae Infections
- Spinal Cord Diseases
- Myelitis
- Poliomyelitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- LG-VCCL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poliomyelitis
-
Uniformed Services University of the Health SciencesUnknown
-
GlaxoSmithKlineCompletedPoliomyelitis | Poliomyelitis VaccinesChina
-
University Hospital, MontpellierCompletedPoliomyelitis SequelaeFrance
-
University Hospital, MontpellierCompletedPost-Poliomyélitis SyndromFrance
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and Prevention; Government of BangladeshNot yet recruiting
-
Institut de Sante Parasport Connecte SynergiesAssistance Publique - Hôpitaux de ParisRecruiting
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, BangladeshCompleted
-
Centers for Disease Control and PreventionInternational Centre for Diarrhoeal Disease Research, Bangladesh; World Health... and other collaboratorsEnrolling by invitation
-
Pierre Van DammeBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PA... and other collaboratorsCompleted
-
Sinovac Biotech Co., LtdCompleted
Clinical Trials on Inactivated Poliomyelitis Vaccine (Sabin strain)
-
Institute of Medical Biology, Chinese Academy of...Shanghai Center for Disease Control and PreventionCompleted
-
Cancer Institute and Hospital, Chinese Academy...Guangxi Center for Disease Control and Prevention; National Institute for the...Completed
-
Institute of Medical Biology, Chinese Academy of...Guangxi Center for Disease Control and Prevention; National Institute for the...Completed
-
Centers for Disease Control and Prevention, ChinaWorld Health Organization; Shandong Province Centers for Disease Control and...Completed
-
Pauline VerdijkWorld Health OrganizationCompleted
-
TakedaTerminated
-
Pauline VerdijkWorld Health OrganizationCompleted
-
Centers for Disease Control and Prevention, ChinaWorld Health Organization; Shandong Province Centers for Disease Control and...Completed
-
Centers for Disease Control and Prevention, ChinaShandong Province Centers for Disease Control and PreventionCompleted
-
Sinovac Biotech Co., LtdRecruitingPoliomyelitis | PolioPakistan, Bangladesh